In this article:

Evercore ISI Maintains Their Buy Rating on Longboard Pharmaceuticals (LBPH)

In this article:
In this article:

In a report released today, Maneka Mirchandaney from Evercore ISI maintained a Buy rating on Longboard Pharmaceuticals (LBPHResearch Report), with a price target of $35.00. The company’s shares closed last Tuesday at $9.05, close to its 52-week low of $7.39.

According to TipRanks.com, Mirchandaney is a 2-star analyst with an average return of 9.6% and a 70.0% success rate. Mirchandaney covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Inc., Finch Therapeutics Group, and Codiak BioSciences.

Currently, the analyst consensus on Longboard Pharmaceuticals is a Moderate Buy with an average price target of $35.00.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.

Read More on LBPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed